Toronto, Ontario--(Newsfile Corp. - November 24, 2014) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of ECG acquisition and management software solutions is pleased to announce a four year agreement with GE Healthcare's Diagnostic Cardiology division which will see GE Healthcare recommending their MARS® Event software customer base, upgrade to the GEMS™ WIN platform. All upgrades will be performed by CardioComm Solutions directly.
The GE Healthcare / CardioComm Solutions relationship has been in place for the past eight (8) years during which time CardioComm Solutions has been providing GE HealthCare software under an OEM agreement. With Microsoft's announcement that Windows XP and Server 2003 support would be discontinued in 2014 and 2015 respectively, GE Healthcare decided that GEMS™ WIN and GEMS™ Lite would be sold in favour of the MARS® Event Station and MARS® Event Station Lite and that the MARS® Event Station and that the MARS® software will no longer be sold.
The recently released GEMS™ WIN and GEMS™ Lite software will provide the same user interface and capabilities of the MARS® Event and Event Lite solutions which will make the transition of an upgrade straight forward and not require staff retraining. In addition, GEMS™ WIN users may take advantage of the integration of new digital and wireless event recorders into their monitoring services as well as retain use of their legacy analogue ECG recorder devices.
CardioComm Solutions and GE Healthcare have reported a long collaborative relationship of ensuring that hospitals and physicians have continued access to the latest ambulatory ECG event management solutions available.
Under the terms of the agreement, GE Healthcare has agreed to actively work with CardioComm Solutions to inform MARS© Software users, or other relevant GEHC clients, that the recently released GEMS™ Software is the next generation release of the MARS© Software for use within a Windows 7 and Server 2008 operating system. Promotion of an upgrade to the GEMS™ Software will be accomplished through a collaborative and joint communication strategy which will include the use of the GEHC salesforce. This agreement will remain in place with annual renewals, until June 2018.
CardioComm Solutions has been successfully selling the GEMS™ WIN software upgrade into its own customer database since June of this year. This agreement adds a new list of prospects that CardioComm Solutions' sales force will be interacting with actively.
To learn more about the CardioComm Solutions products please see the Company's website www.cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should: specifically consider risks discussed under the heading "Risk Factors" in the Company's Annual Information Form, available at www.sedar.com; not to place undue reliance on forward-looking statements and forward-looking information; be aware the Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this Annual Information Form other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
